GS-98-437. A double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results - Marcellin,P.; Chang,T-T.; Lim,S.G. (Hepatology, 2001)